BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Calendar//CN-US Event Research//ZH
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Calendar
X-WR-CALDESC:Market-moving event research, reminders and post-event review.
BEGIN:VEVENT
UID:evt-fda-pharmacy-compounding-peptide-adcomm-july2026@catalyst-calendar.local
DTSTAMP:20260720T200554Z
DTSTART:20260723T120000Z
DTEND:20260723T123000Z
SUMMARY:FDA药房配制咨询委员会审议多种肽类原料503A清单窗口
DESCRIPTION:FDA Pharmacy Compounding Advisory Committee将于7月23日至24日讨论BPC-157、KPV、TB-500、MOTS-c、Semax、Epitalon等多种肽类原料是否纳入503A Bulks List；该窗口可能影响美国配制药房、肽类保健/减重灰色供给和监管收紧预期。\\nImpact score: 61\\nExpected: 委员会建议、FDA后续政策倾向和背景文件对配制肽类产品可及性与合规成本的影响。\\nAffected: EL(theme\, mixed\, score 46)\; NVO(theme\, mixed\, score 46)\; XBI(etf\, mixed\, score 42)\; MACRO(macro_beta\, unknown\, score 62)\\nSources: FDA Pharmacy Compounding Advisory Committee announcement: https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026\\nInformation only. Not investment advice.
URL:https://0.0.0.0:3000/?event=evt-fda-pharmacy-compounding-peptide-adcomm-july2026
CATEGORIES:policy\,MACRO\,FDA\,advisory committee\,compounding\,peptides\,503A
SEQUENCE:0
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:Review catalyst preview: FDA药房配制咨询委员会审议多种肽类原料503A清单窗口
END:VALARM
BEGIN:VALARM
TRIGGER:PT24H
ACTION:DISPLAY
DESCRIPTION:Complete post-event review: FDA药房配制咨询委员会审议多种肽类原料503A清单窗口
END:VALARM
END:VEVENT
END:VCALENDAR